BCL2 and acute myeloid leukemia: Consequently, targeted therapies have been developed and recently approved for the treatment of AML, including agents that target FMS-like tyrosine kinase 3 (FLT3), isocitrate dehydrogenase (IDH), and Bcl-2 (Shimada, 2019).